Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 5/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.32 |
| ▸ | AKT2 | P31751 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713355 | 0.86 | HTR2A (0.33) | PDE4DAKT1AKT2 | |
| SCHEMBL361527 | 0.78 | MAPT (0.38) | POLBAKT1AKT2TP53 | |
| SCHEMBL2969079 | 0.77 | KDM4E (0.49) | TP53 | |
| SCHEMBL5439370 | 0.75 | PDE10A (0.31) | PDE10A | |
| SCHEMBL5447564 | 0.74 | MEN1 (0.30) | — | |
| SCHEMBL14430549 | 0.74 | TRPV1 (0.36) | — | |
| SCHEMBL2964035 | 0.73 | ALDH1A1 (0.43) | FABP4FABP5PDE10APOLBTP53 | |
| SCHEMBL2964668 | 0.73 | PTGS1 (0.36) | FABP4FABP5POLBTP53 | |
| SCHEMBL5447381 | 0.72 | IDH1 (0.35) | — | |
| SCHEMBL5452647 | 0.70 | PDE4D (0.44) | PDE4DPDE4AGRM5ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184273-A1 | BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184273-A1 | BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| WO-2012007416-A1 | BICYCLIC PYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184273-A1 | BICYCLIC PYRIMIDINES | PIK3CA, TYMS, PIK3CD | PDE4D 1655/4885FABP4 4469/4885FABP5 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.